Immunotherapy is a promising treatment modality that acts by selectively harnessing the host immune defenses against cancer. An effective immune response is often needed to eliminate tumors following treatment which can trigger the immunogenicity of dying tumor cells. Some treatment modalities (such as photodynamic therapy, high hydrostatic pressure or radiotherapy) and agents (some chemotherapeutic agents, oncolytic viruses) have been used to endow tumor cells with immunogenicity and/or increase their immunogenicity. These treatments and agents can boost the antitumor capacity by inducing immune responses against tumor neoantigens. Immunogenic cell death is a manner of cell death that can induce the emission of immunogenic damage-associated molecular patterns (DAMPs). DAMPs are sufficient for immunocompetent hosts to trigger the immune system. This review focuses on the latest developments in the treatment modalities and agents that can induce and/or enhance the immunogenicity of cancer cells.
PapaioannouNEBeniataOVVitsosPTsitsilonisOSamaraP. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4(14):261.
2.
KroemerGGalluzziLKeppOZitvogelL. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51-72.
3.
KryskoDVGargADKaczmarekAKryskoOAgostinisPVandenabeeleP. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860-875.
4.
YinSYEfferthTJianFYet al. Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1. Oncotarget. 2016;7(28):43629-43653.
5.
KeppOGalluzziLMartinsIet al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30(1):61-69.
6.
DudekAMGargADKryskoDVDe RuysscherDAgostinisP. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev. 2013;24(4):319-333.
7.
GargADNowisDGolabJVandenabeelePKryskoDVAgostinisP. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta. 2010;1805(1):53-71.
8.
GardaiSJMcPhillipsKAFraschSCet al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123(2):321-334.
9.
HankeNAlizadehDKatsanisELarmonierN. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol. 2013;33(1):1-21.
10.
GhiringhelliFApetohLTesniereAet al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15(10):1170-1178.
11.
ElliottMRChekeniFBTrampontPCet al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461(7261):282-286.
12.
MartinsIWangYMichaudMet al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014;21(1):79-91.
13.
la SalaASebastianiSFerrariDet al. Dendritic cells exposed to extracellular adenosine triphosphate acquire the migratory properties of mature cells and show a reduced capacity to attract type 1 T lymphocytes. Blood. 2002;99(5):1715-1722.
14.
ZhangYGongLHZhangHQet al. Extracellular ATP enhances in vitro invasion of prostate cancer cells by activating Rho GTPase and upregulating MMPs expression. Cancer Lett. 2010;293(2):189-197.
15.
IdzkoMHammadHvan NimwegenMet al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. 2007;13(8):913-919.
16.
TesniereAPanaretakisTKeppOet al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15(1):3-12.
17.
SpisekRDhodapkarMV. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle. 2007;6(16):1962-1965.
18.
PisetskyDSGauleyJUllalAJ. HMGB1 and microparticles as mediators of the immune response to cell death. Antioxid Redox Signal. 2011;15(8):2209-2219.
19.
ApetohLGhiringhelliFTesniereAet al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050-1059.
20.
DiaconuICerulloVHirvinenMLet al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 2012;72(9):2327-2338.
21.
FucikovaJMoserovaITruxovaIet al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 2014;135(5):1165-1177.
22.
ChenHMWangPHChenSSet al. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunol Immunother. 2012;61(11):1989-2002.
23.
DEliseoDManziLVelottiF. Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones. 2013;18(6):801-808.
24.
KeppOSenovillaLVitaleIet al. Consensus guidelines for the detection of immunogenic cell death. OncoImmunology. 2014;3(9):e955691.
25.
GarnettCTSchlomJHodgeJW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008;14(11):3536-3544.
26.
VacchelliEArandaFEggermontAet al. Trial Watch: Chemotherapy with immunogenic cell death inducers. OncoImmunology. 2014;3(1):e27878.
27.
GalluzziLSenovillaLVitaleIet al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869-1883.
28.
PanaretakisTKeppOBrockmeierUet al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28(5):578-590.
29.
ZhaoXYangKZhaoRet al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials. 2016;102:187-197.
30.
EmadiAJonesRJBrodskyRA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6(11):638-647.
31.
SchiavoniGSistiguAValentiniMet al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011;71(3):768-778.
32.
VandenabeelePGalluzziLVanden BergheTKroemerG. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11(10):700-714.
DemariaSSantoriFRNgBLiebesLFormentiSCVukmanovicS. Select forms of tumor cell apoptosis induce dendritic cell maturation. J Leukoc Biol. 2005;77(3):361-368.
35.
SchumacherLYVoDDGarbanHJet al. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol. 2006;176(8):4757-4765.
36.
CironeMDi RenzoLLottiLVet al. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS ONE. 2012;7(3):e31732.
37.
HodgeJWGarnettCTFarsaciBet al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133(3):624-636.
38.
MahoneyDJStojdlDF. Molecular pathways: multimodal cancer-killing mechanisms employed by oncolytic vesiculoviruses. Clin Cancer Res. 2013;19(4):758-763.
39.
WorkenheSTMossmanKL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther. 2014;22(2):251-256.
40.
PandhaHS. Science in focus – Oncolytic viruses: new multifunctional immunotherapeutics. Clin Oncol (R Coll Radiol). 2016;28(10):615-618.
41.
InoueHTaniK. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014;21(1):39-49.
42.
HeinrichBKleinJDelicMet al. Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. Onco Targets Ther. 2017;10:2389-2401.
43.
McConkeyDJ. RAIDDing ER stress for oncolytic viral therapy. Cancer Cell. 2011;20(4):416-418.
44.
GuoZSLiuZBartlettDL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014;4:74.
45.
DonnellyOGErrington-MaisFSteeleLet al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2013;20(1):7-15.
46.
KoksCAGargADEhrhardtMet al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer. 2015;136(5):E313-E325.
47.
TakasuAMasuiAHamadaMImaiTIwaiSYuraY. Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. Cancer Gene Ther. 2016;23(4):107-113.
48.
MiyamotoSInoueHNakamuraTet al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72(10):2609-2621.
49.
LangfieldKKWalkerHJGregoryLCFederspielMJ. Manufacture of measles viruses. Methods Mol Biol. 2011;737:345-366.
50.
WorkenheSTSimmonsGPolJGLichtyBDHalfordWPMossmanKL. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther. 2014;22(1):123-131.
51.
DuewellPStegerALohrHet al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ. 2014;21(12):1825-1837.
52.
BoozariBMundtBWollerNet al. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut. 2010;59(10):1416-1426.
53.
GoldenEBPellicciottaIDemariaSBarcellos-HoffMHFormentiSC. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol. 2012;2:88.
54.
DemariaSNgBDevittMLet al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862-870.
55.
ThompsonRFMaityA. Radiotherapy and the tumor microenvironment: mutual influence and clinical implications. Adv Exp Med Biol. 2014;772:147-165.
56.
GorinJBMénagerJGouardSet al. Antitumor immunity induced after α irradiation. Neoplasia. 2014;16(4):319-328.
57.
GameiroSRJammehMLWattenbergMMTsangKYFerroneSHodgeJW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5(2):403-416.
58.
SongKHJungSYKangSMet al. Induction of immunogenic cell death by radiation-upregulated karyopherin alpha 2 in vitro. Eur J Cell Biol. 2016;95(6-7):219-227.
59.
CacanESpringAMKumariAGreerSFGarnett-BensonC. Combination treatment with sublethal ionizing radiation and the proteasome inhibitor, bortezomib, enhances death-receptor mediated apoptosis and anti-tumor immune attack. Int J Mol Sci. 2015;16(12):30405-30421.
AgostinisPBergKCengelKAet al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250-281.
62.
QinJKundaNQiaoGet al. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell Death Dis. 2017;8(2):e2584.
63.
PlaetzerKKrammerBBerlandaJBerrFKiesslichT. Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci. 2009;24(2):259-268.
64.
JiJFanZZhouFet al. Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncotarget. 2015;6(19):17135-17146.
65.
PanzariniEInguscioVFimiaGMDiniL. Rose bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of damage-associated molecular patterns (DAMPs) in human HeLa cells. PLoS ONE. 2014;9(8):e105778.
66.
TanakaMKataokaHYanoSet al. Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin). Oncotarget. 2016;7(30):47242-47251.
67.
WangXLWangHWWangHSXuSZLiaoKHHillemannsP. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. Br J Dermatol. 2004;151(4):880-885.
68.
UrbanovaLHradilovaNMoserovaIet al. High hydrostatic pressure affects antigenic pool in tumor cells: implication for dendritic cell-based cancer immunotherapy. Immunol Lett. 2017;187:27-34.
69.
HradilovaNSadilkovaLPalataOet al. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. PLoS ONE. 2017;12(2):e0171539.
70.
AdkinsIFucikovaJGargADAgostinisPŠpíšekR. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. OncoImmunology. 2015;3(12):e968434.
71.
MikyškováRŠtěpánekIIndrováMet al. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. Int J Oncol. 2016;48(3):953-964.
72.
LiikanenIAhtiainenLHirvinenMLet al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther. 2013;21(6):1212-1223.
73.
WerthmöllerNFreyBRückertMLotterMFietkauRGaiplUS. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo. Int J Hyperthermia. 2016;32(1):23-30.
74.
MartinsIKeppOSchlemmerFet al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene. 2011;30(10):1147-1158.
75.
KeppOMengerLVacchelliEet al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev. 2013;24(4):311-318.
ArandaFBloyNPesquetJet al. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene. 2015;34(23):3053-3062.
78.
BénéteauMZuninoBJacquinMAet al. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc Natl Acad Sci USA. 2012;109(49):20071-20076.
79.
BuoncervelloMBorghiPRomagnoliGet al. Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. Neoplasia. 2012;14(9):855-867.
80.
ZhaoTRenHJiaLet al. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget. 2015;6(4):2250-2262.
81.
AndújarIRecioMCGinerRMRíosJL. Traditional Chinese medicine remedy to jury: the pharmacological basis for the use of shikonin as an anticancer therapy. Curr Med Chem. 2013;20(23):2892-2898.
82.
LuoXJPengJLiYJ. Recent advances in the study on capsaicinoids and capsinoids. Eur J Pharmacol. 2011;650(1):1-7.
83.
GranatoMGilardini MontaniMSFilardiMFaggioniACironeM. Capsaicin triggers immunogenic PEL cell death, stimulates DCs and reverts PEL-induced immune suppression. Oncotarget. 2015;6(30):29543-29554.
84.
CironeMLucaniaGAleandriSet al. Suppression of dendritic cell differentiation through cytokines released by primary effusion lymphoma cells. Immunol Lett. 2008;120(1-2):37-41.
85.
ZitvogelLKeppOKroemerG. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151-160.
